
Conference Coverage
Latest News

BPH treatment patterns: Understanding regional differences in baseline ED treatment

Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC

Rethinking Testosterone Therapy After the FDA Label Revisions

FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC

The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD

Shorts










Videos
Urology Times Digital Edition







All News

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

enGene expects to initiate a BLA submission by the end of 2026.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.

Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.

The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.

These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.







































